Treatment of dyslipidemia in HIV-infected patients

Bibliography

• Madge S, Kinloch-de-Loes S, Mercey D, Lipodystrophy in patients naive to HIV protease inhibitors. AIDS 1999;13:735-7
   PubMed Web of Science ®Google Scholar
• Young J, Rickenbach M, Weber R, Body fat changes among antiretroviral-naive patients on PI- and NNRTI-based HAART in the Swiss HIV cohort study. Antivir Ther 2005;10:73-81
   PubMedGoogle Scholar
• Fourie CM, Van Rooyen JM, Kruger A, Schutte AE. Lipid abnormalities in a never-treated HIV-1 subtype C-infected African population. Lipids 2010;45:73-80
   PubMedGoogle Scholar
• De Wit S, Sabin CA, Weber R, Incidence and risk factors for new-onset diabetes in HIV-infected patients: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study. Diabetes Care 2008;31:1224-9
   PubMed Web of Science ®Google Scholar
• Worm SW, Sabin C, Weber R, Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D:A:D) study. J Infect Dis 2010;201(3):318-30
   PubMedGoogle Scholar
• Crum-Cianflone N, Dilay A, Collins G, Nonalcoholic fatty liver disease among HIV-infected persons. J Acquir Immune Defic Syndr 2009;50:464-73
   PubMed Web of Science ®Google Scholar
• Dube MP, Stein JH, Aberg JA, Guidelines for the evaluation and management of dyslipidemia in human immunodeficiency virus (HIV)-infected adults receiving antiretroviral therapy: recommendations of the HIV Medical Association of the Infectious Disease Society of America and the Adult AIDS Clinical Trials Group. Clin Infect Dis 2003;37:613-27
   PubMed Web of Science ®Google Scholar
• Hulgan T, Sterling TR, Daugherty J, Prescribing of contraindicated protease inhibitor and statin combinations among HIV-infected persons. J Acquir Immune Defic Syndr 2005;38:277-82
   PubMed Web of Science ®Google Scholar
• Sekhar RV, Jahoor F, White AC, Metabolic basis of HIV-lipodystrophy syndrome. Am J Physiol Endocrinol Metab 2002;283:E332-7
   PubMed Web of Science ®Google Scholar
• Reeds DN, Mittendorfer B, Patterson BW, Alterations in lipid kinetics in men with HIV-dyslipidemia. Am J Physiol Endocrinol Metab 2003;285:E490-7
   PubMed Web of Science ®Google Scholar
• Sekhar RV, Jahoor F, Pownall HJ, Severely dysregulated disposal of postprandial triacylglycerols exacerbates hypertriacylglycerolemia in HIV lipodystrophy syndrome. Am J Clin Nutr 2005;81:1405-10
   PubMedGoogle Scholar
• Ware LJ, Wootton SA, Morlese JM, The paradox of improved antiretroviral therapy in HIV: potential for nutritional modulation? Proc Nutr Soc 2002;61:131-6
   PubMedGoogle Scholar
• Periard D, Telenti A, Sudre P, Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors. The Swiss HIV Cohort Study. Circulation 1999;100:700-5
   PubMed Web of Science ®Google Scholar
• Purnell JQ, Zambon A, Knopp RH, Effect of ritonavir on lipids and post-heparin lipase activities in normal subjects. AIDS 2000;14:51-7
   PubMed Web of Science ®Google Scholar
• Carr A, Samaras K, Thorisdottir A, Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet 1999;353:2093-9
   PubMed Web of Science ®Google Scholar
• Mulligan K, Grunfeld C, Tai VW, Hyperlipidemia and insulin resistance are induced by protease inhibitors independent of changes in body composition in patients with HIV infection. J Acquir Immune Defic Syndr 2000;23:35-43
   PubMed Web of Science ®Google Scholar
• Behrens G, Dejam A, Schmidt H, Impaired glucose tolerance, beta cell function and lipid metabolism in HIV patients under treatment with protease inhibitors. AIDS 1999;13:F63-70
   PubMed Web of Science ®Google Scholar
• Friis-Moller N, Weber R, Reiss P, Cardiovascular disease risk factors in HIV patients–association with antiretroviral therapy. Results from the DAD study. AIDS 2003;17:1179-93
   PubMed Web of Science ®Google Scholar
• Grunfeld C, Kotler DP, Hamadeh R, Hypertriglyceridemia in the acquired immunodeficiency syndrome. Am J Med 1989;86:27-31
   PubMed Web of Science ®Google Scholar
• Grunfeld C, Pang M, Doerrler W, Lipids, lipoproteins, triglyceride clearance, and cytokines in human immunodeficiency virus infection and the acquired immunodeficiency syndrome. J Clin Endocrinol Metab 1992;74:1045-52
   PubMed Web of Science ®Google Scholar
• Constans J, Pellegrin JL, Peuchant E, Plasma lipids in HIV-infected patients: a prospective study in 95 patients. Eur J Clin Invest 1994;24:416-20
   PubMed Web of Science ®Google Scholar
• Rose H, Hoy J, Woolley I, HIV infection and high density lipoprotein metabolism. Atherosclerosis 2008;199:79-86
   PubMed Web of Science ®Google Scholar
• Mujawar Z, Rose H, Morrow MP, Human immunodeficiency virus impairs reverse cholesterol transport from macrophages. PLoS Biol 2006;4(11):e365, 1970-83
   Google Scholar
• Tsiodras S, Mantzoros C, Hammer S, Samore M. Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy: a 5-year Cohort Study. Arch Intern Med 2000;160:2050-6
   PubMed Web of Science ®Google Scholar
• Fellay J, Boubaker K, Ledergerber B, Prevalence of adverse events associated with potent antiretroviral treatment: Swiss HIV Cohort Study. Lancet 2001;358:1322-7
   PubMed Web of Science ®Google Scholar
• Hatano H, Miller KD, Yoder CP, Metabolic and anthropometric consequences of interruption of highly active antiretroviral therapy. AIDS 2000;14:1935-42
   PubMed Web of Science ®Google Scholar
• Mobius U, Lubach-Ruitman M, Castro-Frenzel B, Switching to atazanavir improves metabolic disorders in antiretroviral-experienced patients with severe hyperlipidemia. J Acquir Immune Defic Syndr 2005;39:174-80
   PubMed Web of Science ®Google Scholar
• van der Valk M, Gisolf EH, Reiss P, Increased risk of lipodystrophy when nucleoside analogue reverse transcriptase inhibitors are included with protease inhibitors in the treatment of HIV-1 infection. AIDS 2001;15:847-55
   PubMed Web of Science ®Google Scholar
• Jones R, Sawleshwarkar S, Michailidis C, Impact of antiretroviral choice on hypercholesterolaemia events: the role of the nucleoside reverse transcriptase inhibitor backbone. HIV Med 2005;6:396-402
   PubMed Web of Science ®Google Scholar
• van der Valk M, Bisschop PH, Romijn JA, Lipodystrophy in HIV-1-positive patients is associated with insulin resistance in multiple metabolic pathways. AIDS 2001;15:2093-100
   PubMedGoogle Scholar
• Murata H, Hruz PW, Mueckler M. Indinavir inhibits the glucose transporter isoform Glut4 at physiologic concentrations. AIDS 2002;16:859-63
   PubMed Web of Science ®Google Scholar
• Hadigan C, Meigs JB, Corcoran C, Metabolic abnormalities and cardiovascular disease risk factors in adults with human immunodeficiency virus infection and lipodystrophy. Clin Infect Dis 2001;32:130-9
   PubMed Web of Science ®Google Scholar
• Shikuma CM, Day LJ, Gerschenson M. Insulin resistance in the HIV-infected population: the potential role of mitochondrial dysfunction. Curr Drug Targets Infect Disord 2005;5:255-62
   PubMedGoogle Scholar
• Gan SK, Samaras K, Thompson CH, Altered myocellular and abdominal fat partitioning predict disturbance in insulin action in HIV protease inhibitor-related lipodystrophy. Diabetes 2002;51:3163-9
   PubMed Web of Science ®Google Scholar
• Sutinen J, Hakkinen AM, Westerbacka J, Increased fat accumulation in the liver in HIV-infected patients with antiretroviral therapy-associated lipodystrophy. AIDS 2002;16:2183-93
   PubMed Web of Science ®Google Scholar
• Addy CL, Gavrila A, Tsiodras S, Hypoadiponectinemia is associated with insulin resistance, hypertriglyceridemia, and fat redistribution in human immunodeficiency virus-infected patients treated with highly active antiretroviral therapy. J Clin Endocrinol Metab 2003;88:627-36
   PubMed Web of Science ®Google Scholar
• Samaras K, Wand H, Law M, Prevalence of metabolic syndrome in HIV-infected patients receiving highly active antiretroviral therapy using International Diabetes Foundation and Adult Treatment Panel III criteria: associations with insulin resistance, disturbed body fat compartmentalization, elevated C-reactive protein, and [corrected] hypoadiponectinemia. Diabetes Care 2007;30:113-19
   PubMed Web of Science ®Google Scholar
• Kim RJ, Carlow DC, Rutstein JH, Hypoadiponectinemia, dyslipidemia, and impaired growth in children with HIV-associated facial lipoatrophy. J Pediatr Endocrinol Metab 2007;20:65-74
   PubMedGoogle Scholar
• Unal A, Torun E, Sipahioglu MH, Fenofibrate-induced acute renal failure due to massive rhabdomyolysis after coadministration of statin in two patients. Intern Med 2008;47:1017-19
   PubMed Web of Science ®Google Scholar
• Wu J, Song Y, Li H, Chen J. Rhabdomyolysis associated with fibrate therapy: review of 76 published cases and a new case report. Eur J Clin Pharmacol 2009;65:1169-74
   PubMed Web of Science ®Google Scholar
• Schmidt GA, Hoehns JD, Purcell JL, Severe rhabdomyolysis and acute renal failure secondary to concomitant use of simvastatin, amiodarone, and atazanavir. J Am Board Fam Med 2007;20:411-16
   PubMed Web of Science ®Google Scholar
• Mikhail N, Iskander E, Cope D. Rhabdomyolysis in an HIV-infected patient on anti-retroviral therapy precipitated by high-dose pravastatin. Curr Drug Saf 2009;4:121-2
   PubMedGoogle Scholar
• Silverberg MJ, Leyden W, Hurley L, Response to newly prescribed lipid-lowering therapy in patients with and without HIV infection. Ann Intern Med 2009;150:301-13
   PubMed Web of Science ®Google Scholar
• Joy T, Keogh HM, Hadigan C, Dietary fat intake and relationship to serum lipid levels in HIV-infected patients with metabolic abnormalities in the HAART era. AIDS 2007;21:1591-600
   PubMedGoogle Scholar
• Hsyu PH, Schultz-Smith MD, Lillibridge JH, Pharmacokinetic interactions between nelfinavir and 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors atorvastatin and simvastatin. Antimicrob Agents Chemother 2001;45:3445-50
   PubMed Web of Science ®Google Scholar
• Benesic A, Zilly M, Kluge F, Lipid lowering therapy with fluvastatin and pravastatin in patients with HIV infection and antiretroviral therapy: comparison of efficacy and interaction with indinavir. Infection 2004;32:229-33
   PubMed Web of Science ®Google Scholar
• Calza L, Colangeli V, Manfredi R, Rosuvastatin for the treatment of hyperlipidaemia in HIV-infected patients receiving protease inhibitors: a pilot study. AIDS 2005;19:1103-5
   PubMed Web of Science ®Google Scholar
• Johns KW, Bennett MT, Bondy GP. Are HIV+ patients resistant to statin therapy? Lipids Health Dis 2007;6:27
   PubMedGoogle Scholar
• Baldini F, Di Giambenedetto S, Cingolani A, Efficacy and tolerability of pravastatin for the treatment of HIV-1 protease inhibitor-associated hyperlipidaemia: a pilot study. AIDS 2000;14:1660-2
   PubMed Web of Science ®Google Scholar
• Moyle GJ, Lloyd M, Reynolds B, Dietary advice with or without pravastatin for the management of hypercholesterolaemia associated with protease inhibitor therapy. AIDS 2001;15:1503-8
   PubMed Web of Science ®Google Scholar
• Aberg JA, Zackin RA, Brobst SW, A randomized trial of the efficacy and safety of fenofibrate versus pravastatin in HIV-infected subjects with lipid abnormalities: AIDS Clinical Trials Group Study 5087. AIDS Res Hum Retroviruses 2005;21:757-67
   PubMed Web of Science ®Google Scholar
• Doser N, Kubli S, Telenti A, Efficacy and safety of fluvastatin in hyperlipidemic protease inhibitor-treated HIV-infected patients. AIDS 2002;16:1982-3
   PubMedGoogle Scholar
• Palacios R, Santos J, Gonzalez M, Efficacy and safety of atorvastatin in the treatment of hypercholesterolemia associated with antiretroviral therapy. J Acquir Immune Defic Syndr 2002;30:536-7
   PubMed Web of Science ®Google Scholar
• Bottaro EG, Caravello O, Scapellato PG, Rosuvastatin for the treatment of dyslipidemia in HIV-infected patients receiving highly active antiretroviral therapy. Preliminary experience. Enferm Infecc Microbiol Clin 2008;26:325-9
   PubMedGoogle Scholar
• Calza L, Manfredi R, Colangeli V, Rosuvastatin, pravastatin, and atorvastatin for the treatment of hypercholesterolaemia in HIV-infected patients receiving protease inhibitors. Curr HIV Res 2008;6:572-8
   PubMed Web of Science ®Google Scholar
• Aslangul E, Assoumou L, Bittar R, Rosuvastatin versus pravastatin in dyslipidemic HIV-1-infected patients receiving protease inhibitors: a randomized trial. AIDS 2010;24:77-83
   PubMed Web of Science ®Google Scholar
• Rao A, D'Amico S, Balasubramanyam A, Maldonado M. Fenofibrate is effective in treating hypertriglyceridemia associated with HIV lipodystrophy. Am J Med Sci 2004;327:315-18
   PubMed Web of Science ®Google Scholar
• Calza L, Manfredi R, Chiodo F. Statins and fibrates for the treatment of hyperlipidaemia in HIV-infected patients receiving HAART. AIDS 2003;17:851-9
   PubMed Web of Science ®Google Scholar
• Badiou S, Merle De Boever C, Dupuy AM, Fenofibrate improves the atherogenic lipid profile and enhances LDL resistance to oxidation in HIV-positive adults. Atherosclerosis 2004;172:273-9
   PubMed Web of Science ®Google Scholar
• Miller J, Brown D, Amin J, A randomized, double-blind study of gemfibrozil for the treatment of protease inhibitor-associated hypertriglyceridaemia. AIDS 2002;16:2195-200
   PubMed Web of Science ®Google Scholar
• Coll B, Aragones G, Parra S, Ezetimibe effectively decreases LDL-cholesterol in HIV-infected patients. AIDS 2006;20:1675-7
   PubMed Web of Science ®Google Scholar
• Gagne C, Bays HE, Weiss SR, Efficacy and safety of ezetimibe added to ongoing statin therapy for treatment of patients with primary hypercholesterolemia. Am J Cardiol 2002;90:1084-91
   PubMed Web of Science ®Google Scholar
• Pearson TA, Denke MA, McBride PE, A community-based, randomized trial of ezetimibe added to statin therapy to attain NCEP ATP III goals for LDL cholesterol in hypercholesterolemic patients: the ezetimibe add-on to statin for effectiveness (EASE) trial. Mayo Clin Proc 2005;80:587-95
   PubMed Web of Science ®Google Scholar
• Negredo E, Molto J, Puig J, Ezetimibe, a promising lipid-lowering agent for the treatment of dyslipidaemia in HIV-infected patients with poor response to statins. AIDS 2006;20:2159-64
   PubMed Web of Science ®Google Scholar
• Dube MP, Wu JW, Aberg JA, Safety and efficacy of extended-release niacin for the treatment of dyslipidaemia in patients with HIV infection: AIDS Clinical Trials Group Study A5148. Antivir Ther 2006;11:1081-9
   PubMed Web of Science ®Google Scholar
• Chow DC, Tasaki A, Ono J, Effect of extended-release niacin on hormone-sensitive lipase and lipoprotein lipase in patients with HIV-associated lipodystrophy syndrome. Biologics 2008;2:917-21
   PubMedGoogle Scholar
• Slama L, Lanoy E, Valantin MA, Effect of pioglitazone on HIV-1-related lipodystrophy: a randomized double-blind placebo-controlled trial (ANRS 113). Antivir Ther 2008;13:67-76
   PubMed Web of Science ®Google Scholar
• Gavrila A, Hsu W, Tsiodras S, Improvement in highly active antiretroviral therapy-induced metabolic syndrome by treatment with pioglitazone but not with fenofibrate: a 2 × 2 factorial, randomized, double-blinded, placebo-controlled trial. Clin Infect Dis 2005;40:745-9
   PubMed Web of Science ®Google Scholar
• Hadigan C, Mazza S, Crum D, Grinspoon S. Rosiglitazone increases small dense low-density lipoprotein concentration and decreases high-density lipoprotein particle size in HIV-infected patients. AIDS 2007;21:2543-6
   PubMedGoogle Scholar
• Mulligan K, Yang Y, Wininger DA, Effects of metformin and rosiglitazone in HIV-infected patients with hyperinsulinemia and elevated waist/hip ratio. AIDS 2007;21:47-57
   PubMed Web of Science ®Google Scholar
• Kovacic JC, Martin A, Carey D, Influence of rosiglitazone on flow-mediated dilation and other markers of cardiovascular risk in HIV-infected patients with lipoatrophy. Antivir Ther 2005;10:135-43
   PubMedGoogle Scholar
• Sutinen J, Hakkinen AM, Westerbacka J, Rosiglitazone in the treatment of HAART-associated lipodystrophy – a randomized double-blind placebo-controlled study. Antivir Ther 2003;8:199-207
   PubMed Web of Science ®Google Scholar
• Carter VM, Woolley I, Jolley D, A randomised controlled trial of omega-3 fatty acid supplementation for the treatment of hypertriglyceridemia in HIV-infected males on highly active antiretroviral therapy. Sex Health 2006;3:287-90
   PubMedGoogle Scholar
• Wohl DA, Tien HC, Busby M, Randomized study of the safety and efficacy of fish oil (omega-3 fatty acid) supplementation with dietary and exercise counseling for the treatment of antiretroviral therapy-associated hypertriglyceridemia. Clin Infect Dis 2005;41:1498-504
   PubMed Web of Science ®Google Scholar
• Gerber JG, Kitch DW, Fichtenbaum CJ, Fish oil and fenofibrate for the treatment of hypertriglyceridemia in HIV-infected subjects on antiretroviral therapy: results of ACTG A5186. J Acquir Immune Defic Syndr 2008;47:459-66
   PubMed Web of Science ®Google Scholar
• De Truchis P, Kirstetter M, Perier A, Reduction in triglyceride level with N-3 polyunsaturated fatty acids in HIV-infected patients taking potent antiretroviral therapy: a randomized prospective study. J Acquir Immune Defic Syndr 2007;44:278-85
   PubMed Web of Science ®Google Scholar
• Hadigan C, Liebau J, Torriani M, Improved triglycerides and insulin sensitivity with 3 months of acipimox in human immunodeficiency virus-infected patients with hypertriglyceridemia. J Clin Endocrinol Metab 2006;91:4438-44
   PubMed Web of Science ®Google Scholar
• Lo J, You SM, Wei J, Relationship of peak growth hormone to cardiovascular parameters, waist circumference, lipids and glucose in HIV-infected patients and healthy adults. Clin Endocrinol (Oxf) 2009;71(6):815-22
   Google Scholar
• Lo JC, Mulligan K, Noor MA, The effects of low-dose growth hormone in HIV-infected men with fat accumulation: a pilot study. Clin Infect Dis 2004;39:732-5
   PubMed Web of Science ®Google Scholar
• D'Amico S, Shi J, Sekhar RV, Physiologic growth hormone replacement improves fasting lipid kinetics in patients with HIV lipodystrophy syndrome. Am J Clin Nutr 2006;84:204-11
   PubMed Web of Science ®Google Scholar
• Falutz J, Allas S, Blot K, Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med 2007;357:2359-70
   PubMed Web of Science ®Google Scholar
• Lee JH, Chan JL, Sourlas E, Recombinant methionyl human leptin therapy in replacement doses improves insulin resistance and metabolic profile in patients with lipoatrophy and metabolic syndrome induced by the highly active antiretroviral therapy. J Clin Endocrinol Metab 2006;91:2605-11
   PubMed Web of Science ®Google Scholar
• Mulligan K, Khatami H, Schwarz JM, The effects of recombinant human leptin on visceral fat, dyslipidemia, and insulin resistance in patients with human immunodeficiency virus-associated lipoatrophy and hypoleptinemia. J Clin Endocrinol Metab 2009;94:1137-44
   PubMed Web of Science ®Google Scholar
• Hadigan C, Corcoran C, Basgoz N, Metformin in the treatment of HIV lipodystrophy syndrome: a randomized controlled trial. JAMA 2000;284:472-7
   PubMed Web of Science ®Google Scholar
• Hadigan C, Meigs JB, Rabe J, Increased PAI-1 and tPA antigen levels are reduced with metformin therapy in HIV-infected patients with fat redistribution and insulin resistance. J Clin Endocrinol Metab 2001;86:939-43
   PubMed Web of Science ®Google Scholar
• Samson SL, Pownall HJ, Scott LW, Heart positive: design of a randomized controlled clinical trial of intensive lifestyle intervention, niacin and fenofibrate for HIV lipodystrophy/dyslipidemia. Contemp Clin Trials 2006;27:518-30
   PubMed Web of Science ®Google Scholar